Literature DB >> 22648548

Compartment- and malignance-dependent up-regulation of γ-glutamyltranspeptidase and dipetidylpeptidase-IV activity in human brain gliomas.

V Mareš1, J Stremeňová, V Lisá, H Kozáková, J Marek, M Syrůček, O Šoula, A Šedo.   

Abstract

γ-Glutamyltranspeptidase (GGT, syn. γ-Glutamyltransferase) and dipeptidylpeptidase-IV (DPP-IV) activity participates in metabolic and growth control of normal and tumor cells by processing biologically active peptides. Here, we report on up-regulation of these enzymes in human brain gliomas determined by catalytic enzyme histochemistry and immunocytochemistry. Higher activity of GGT was found in 50%, 68% and 81% of WHO grade II, III and IV tumors, respectively. The process started at/near the microvasculature, from where it spread to the parenchyma. On average, the enzyme activity in grade II, III and IV gliomas exceeded controls 2.0, 3.0 and 3.5-fold, respectively. Up-regulation of DPP-IV-like activity also started at the microvasculature, but mainly in pericytes and mononuclear-like cells around the vessels and dispersed in the parenchyma. Marked elevation of this enzyme activity, comprising also tumor parenchyma, occurred only in grade IV glioblastomas (65% patients; 3.6 times above controls) which can, therefore, help in their differentiation from grade III gliomas. The increase of total DPP-IV-like activity also included its two enzymatic homologs, the canonical DPP-IV/CD26 and FAP-1α. The increase in GGT is supposed to be a tumor grade dependent response of microvasculature and tumor astrocytes to stress induced by tissue hypoxia and/or the metabolic aberrancies. The increase in DPP-IV-like activity in high-grade tumors can be attributed to inflammatory/scavenging processes performed by the mononuclear-like cells and, in glioblastomas, also to regressive changes in the structure and function of the microvasculature and tumor parenchyma, including astrocyte stress response. The inverse relationship between DPP-IV-like activity and Ki67 in most glioblastomas and shorter survival time of patients with low activity of this enzyme also suggest its anti-oncogenic effects.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22648548     DOI: 10.14670/HH-27.931

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  6 in total

1.  High DPP4 expression predicts poor prognosis in patients with low-grade glioma.

Authors:  Yadi Han; Yuxue Sun; Yusong Zhang; Qingxin Xia
Journal:  Mol Biol Rep       Date:  2020-02-19       Impact factor: 2.316

Review 2.  Dipeptidyl peptidase-4: a key player in chronic liver disease.

Authors:  Minoru Itou; Takumi Kawaguchi; Eitaro Taniguchi; Michio Sata
Journal:  World J Gastroenterol       Date:  2013-04-21       Impact factor: 5.742

Review 3.  DPPIV/CD26: a tumor suppressor or a marker of malignancy?

Authors:  Aline Beckenkamp; Samuel Davies; Júlia Biz Willig; Andréia Buffon
Journal:  Tumour Biol       Date:  2016-03-04

Review 4.  Glutathione S-conjugates as prodrugs to target drug-resistant tumors.

Authors:  Emma E Ramsay; Pierre J Dilda
Journal:  Front Pharmacol       Date:  2014-08-11       Impact factor: 5.810

5.  Dipeptidylpeptidase--IV, a key enzyme for the degradation of incretins and neuropeptides: activity and expression in the liver of lean and obese rats.

Authors:  E Tarantola; V Bertone; G Milanesi; E Capelli; A Ferrigno; D Neri; M Vairetti; S Barni; I Freitas
Journal:  Eur J Histochem       Date:  2012-10-08       Impact factor: 3.188

6.  DPP4/CD26 overexpression in urothelial carcinoma confers an independent prognostic impact and correlates with intrinsic biological aggressiveness.

Authors:  Peir-In Liang; Bi-Wen Yeh; Wei-Ming Li; Ti-Chun Chan; I-Wei Chang; Chun-Nung Huang; Ching-Chia Li; Hung-Lung Ke; Hsin-Chih Yeh; Wen-Jeng Wu; Chien-Feng Li
Journal:  Oncotarget       Date:  2017-01-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.